December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Molecular Targeting Technologies, Inc.

News headline image
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue Targeted Radiotherapeutic (EB-TRT)
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI 225Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Reports on Fast-Acting Sprayable Molecule to Visualize Tumors for Real-Time Fluorescence-Guided Cytoreductive Surgery
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI at the 2nd Annual Targeted Radionuclide Pharmaceuticals Supply Chain & Manufacturing Summit
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Reports on 225Ac-EBTATE and 177Lu-EBTATE Radiopharmaceuticals at 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
Molecular Targeting Technologies, Inc. to Present EvaThera, Long-Acting Peptide Receptor Radionuclide Therapy Platform, at BioFuture™ 2023
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Announces the Appointment of Dr. Jerry Huang to the Clinical Team
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Announces Favorable Three-Year Follow-Up for EBTATE in Neuroendocrine Tumors
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Obtains FDA Allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
Molecular Targeting Technologies, Inc., Thomas Jefferson University and North China Pharmaceutical Co., Ltd Announced the Chinese Approval for a Rabies Drug
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
Molecular Targeting Technologies, Inc. Announces Spray Technology That Lights Up Tumors
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
Molecular Targeting Technologies, Inc. and University of Antwerp Begin First-in-Human Study of TDURA Diagnostic for Early Detection of Response to Colon Cancer Therapy
From Molecular Targeting Technologies, Inc.
Via Business Wire
News headline image
Molecular Targeting Technologies, Inc. Announces a New PET Imaging Agent for Rapid Monitoring Tumor Response to Therapy
From Molecular Targeting Technologies, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.